Quantification of Early Diffuse Myocardial Fibrosis Through 7.0 T Cardiac Magnetic Resonance T1 Mapping in a Type 1 Diabetic Mellitus Mouse Model

Background Diffuse myocardial interstitial fibrosis (DMIF) is a key factor for heart failure (HF) in diabetic cardiomyopathy. MRI T1‐mapping technique can quantitatively evaluate DMIF. Purpose To evaluate of early DMIF in a type 1 diabetes mellitus (T1DM) mouse model through 7.0 T MRI T1 mapping. Study Type Prospective. Animal Model A total of 50 8‐week‐old C57Bl / 6J male mice were divided into control ( n = 20) and T1DM ( n = 30) groups. Field Strength/Sequence A 7.0 T small animal MRI ; gradient echo Look–Locker inversion recovery T1 ‐mapping sequence; cine MRI . Scans were acquired in control and T1DM mice every 4 weeks until 24 weeks. Assessment End‐diastolic volume (EDV), end‐systolic volume (ESV), ejection fraction (EF), left ventricle (LV) mass, fractional shortening (FS), and E/A ratio. They were evaluated through echocardiography and cine MRI. The extracellular volume fraction (ECV) was calculated. Sirius Red staining was performed and calculated collagen volume fraction (CVF). Statistical Tests Differences in ECV and CVF between two groups were analyzed using one‐way analysis of variance. The correlation between ECV and CVF was assessed using Pearson's correlations. Results Compared with the control group, a progressive decrease in FS, EF, and E/A ratio was observed in the T1DM group. Both ECV and CVF values gradually increased during diabetes progression. A significant increase in ECV and CVF values was observed at 12 weeks (ECV: 32.5% ± 1.6% vs. 28.1% ± 1.8%; CVF: 6.9% ± 1.8% vs. 3.3% ± 1.1%). ECV showed a strong correlation with CVF ( r = 0.856). Data Conclusion ECV is an accurate and feasible imaging marker that can be used to quantitatively assess DMIF changes over time in T1DM mice. ECV has potential to accurately detect DMIF in the early stage and may be a useful imaging tool to assess the need for early intervention in T1DM mice. Evidence Level 1 Technical Efficacy Stage 3.